HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Ramchandani, R. P. Articles by Gobburu, J. V. S. Search for Related Content PubMed PubMed Citation Articles by Ramchandani, R. P. Articles by Gobburu, J. V. S. Social Bookmarking                         What's this?

The Role of SN-38 Exposure, UGT1A1^*28 Polymorphism, and Baseline Bilirubin Level in Predicting Severe Irinotecan Toxicity

From the Office of Clinical Pharmacology (Dr Ramchandani, Dr Wang, Dr Booth, Dr Rahman, Dr Mehta, Dr Gobburu) and the Office of Oncology Drug Products (Dr Ibrahim, Dr Johnson), Center for Drug Evaluation and Research, Food and Drug Administration (FDA), Silver Spring, Maryland, and the Department of Medicine, Committee on Clinical Pharmacology and Pharmacogenomics and Cancer Research Center, University of Chicago, Chicago, Illinois (Dr Innocenti, Dr Ratain).

Irinotecan, an anticancer drug, is associated with severe and potentially fatal diarrhea and neutropenia. The objective of this analysis was to evaluate the role of SN-38 exposure, the active metabolite of irinotecan, UGT1A1 genotypes, and baseline bilirubin on the maximum decrease (nadir) in absolute neutrophil counts following irinotecan. This analysis extended the work of a previous study that examined the effect of UGT1A1 genotypes on the incidence of severe neutropenia in 86 advanced cancer patients following irinotecan treatment. Regression analysis showed that the absolute neutrophil count nadir depended on SN-38 exposure (AUC) and UGT1A1^*28 homozygous 7/7 genotype. An increased SN-38 AUC and the 7/7 genotype were significantly associated with a lower absolute neutrophil count nadir (R² = .49). An alternate model suggested that higher baseline bilirubin and the 7/7 genotype were also significantly associated with a lower absolute neutrophil count nadir, although with a lower coefficient of determination (R² = .31). Based on these findings and other reports, the irinotecan label was modified to indicate the role of UGT1A1^*28 polymorphism in the metabolism of irinotecan and the associated increased risk of severe neutropenia. The label modifications also included recommendations for lower starting doses of irinotecan in patients homozygous for the UGT1A1^*28 (7/7) polymorphism.

Key Words: Irinotecan • SN-38 • neutropenia • UDP-glucuronosyltransferase • genetic polymorphisms

Address for reprints: Roshni P. Ramchandani, PhD, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, US Food and Drug Administration, WO21 Rm 3667, 10903 New Hampshire Ave, Silver Spring, MD 20993; e-mail: roshni.ramchandani{at}fda.hhs.gov.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				C. L.H. Snozek, D. J. O'Kane, and A. Algeciras-Schimnich Pharmacogenetics of Solid Tumors: Directed Therapy in Breast, Lung, and Colorectal Cancer: A Paper from the 2008 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2009; 11(5): 381 - 389. [Abstract] [Full Text] [PDF]

				F. Innocenti, D. L. Kroetz, E. Schuetz, M. E. Dolan, J. Ramirez, M. Relling, P. Chen, S. Das, G. L. Rosner, and M. J. Ratain Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics J. Clin. Oncol., June 1, 2009; 27(16): 2604 - 2614. [Abstract] [Full Text] [PDF]

				R. M. Balliet, G. Chen, C. J. Gallagher, R. W. Dellinger, D. Sun, and P. Lazarus Characterization of UGTs Active against SAHA and Association between SAHA Glucuronidation Activity Phenotype with UGT Genotype Cancer Res., April 1, 2009; 69(7): 2981 - 2989. [Abstract] [Full Text] [PDF]

				D. Czock, F. M. Rasche, B. Boesler, M. Shipkova, and F. Keller Irinotecan in Cancer Patients with End-Stage Renal Failure Ann. Pharmacother., February 1, 2009; 43(2): 363 - 369. [Abstract] [Full Text] [PDF]

				S. A. Veltkamp, E. O. Witteveen, A. Capriati, A. Crea, F. Animati, M. Voogel-Fuchs, I. J.G.M. van den Heuvel, J. H. Beijnen, E. E. Voest, and J. H.M. Schellens Clinical and Pharmacologic Study of the Novel Prodrug Delimotecan (MEN 4901/T-0128) in Patients with Solid Tumors Clin. Cancer Res., November 15, 2008; 14(22): 7535 - 7544. [Abstract] [Full Text] [PDF]

				H. Gurney and R. Shaw Obesity in Dose Calculation: A Mouse or an Elephant? J. Clin. Oncol., October 20, 2007; 25(30): 4703 - 4704. [Full Text] [PDF]